-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on March 8 Recently, Jiangsu Haosen Pharmaceutical has reported frequent successes, following the first review of Decitabine for injection.
On March 3, the official website of the State Food and Drug Administration showed that Jiangsu Haosen Pharmaceutical's vinorelbine tartrate injection was approved as a supplementary application.
Prior to this, vinorelbine tartrate injection had not been reviewed by companies.
According to data from Minai.
com, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
On March 3, the official website of the State Food and Drug Administration showed that Jiangsu Haosen Pharmaceutical's vinorelbine tartrate injection was approved as a supplementary application.
Prior to this, vinorelbine tartrate injection had not been reviewed by companies.
According to data from Minai.
com, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
March 3, 2021 Drug approval certificate pending information release
Vinorelbine tartrate injection is used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.
Source: One-click search on Mi Nei.
com
com
According to data from Menet.
com, in recent years , the sales of Changchun Ruibin injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 100 million yuan.
The growth rate in the first half of 2020 will be more than 100 million yuan.
The decline.
Among them, Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 70%.
There are 9 manufacturers of vinorelbine tartrate injection, including Jiangsu Haosen Pharmaceutical, Qilu Pharmaceutical (Hainan), and Beijing Shuanglu Pharmaceutical.
com, in recent years , the sales of Changchun Ruibin injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 100 million yuan.
The growth rate in the first half of 2020 will be more than 100 million yuan.
The decline.
Among them, Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 70%.
There are 9 manufacturers of vinorelbine tartrate injection, including Jiangsu Haosen Pharmaceutical, Qilu Pharmaceutical (Hainan), and Beijing Shuanglu Pharmaceutical.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of consistency evaluation, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network News on March 8 Recently, Jiangsu Haosen Pharmaceutical has reported frequent successes, following the first review of Decitabine for injection.
On March 3, the official website of the State Food and Drug Administration showed that Jiangsu Haosen Pharmaceutical's vinorelbine tartrate injection was approved as a supplementary application.
Prior to this, vinorelbine tartrate injection had not been reviewed by companies.
According to data from Minai.
com, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
On March 3, the official website of the State Food and Drug Administration showed that Jiangsu Haosen Pharmaceutical's vinorelbine tartrate injection was approved as a supplementary application.
Prior to this, vinorelbine tartrate injection had not been reviewed by companies.
According to data from Minai.
com, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
March 3, 2021 Drug approval certificate pending information release
Vinorelbine tartrate injection is used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.
Source: One-click search on Mi Nei.
com
com
According to data from Menet.
com, in recent years , the sales of Changchun Ruibin injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 100 million yuan.
The growth rate in the first half of 2020 will be more than 100 million yuan.
The decline.
Among them, Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 70%.
There are 9 manufacturers of vinorelbine tartrate injection, including Jiangsu Haosen Pharmaceutical, Qilu Pharmaceutical (Hainan), and Beijing Shuanglu Pharmaceutical.
com, in recent years , the sales of Changchun Ruibin injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 100 million yuan.
The growth rate in the first half of 2020 will be more than 100 million yuan.
The decline.
Among them, Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 70%.
There are 9 manufacturers of vinorelbine tartrate injection, including Jiangsu Haosen Pharmaceutical, Qilu Pharmaceutical (Hainan), and Beijing Shuanglu Pharmaceutical.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of consistency evaluation, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network News on March 8 Recently, Jiangsu Haosen Pharmaceutical has reported frequent successes, following the first review of Decitabine for injection.
On March 3, the official website of the State Food and Drug Administration showed that Jiangsu Haosen Pharmaceutical's vinorelbine tartrate injection was approved as a supplementary application.
Prior to this, vinorelbine tartrate injection had not been reviewed by companies.
According to data from Minai.
com, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
On March 3, the official website of the State Food and Drug Administration showed that Jiangsu Haosen Pharmaceutical's vinorelbine tartrate injection was approved as a supplementary application.
Prior to this, vinorelbine tartrate injection had not been reviewed by companies.
According to data from Minai.
com, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
March 3, 2021 Drug approval certificate pending information release
Vinorelbine tartrate injection is used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.
Source: One-click search on Mi Nei.
com
com
According to data from Menet.
com, in recent years , the sales of Changchun Ruibin injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 100 million yuan.
The growth rate in the first half of 2020 will be more than 100 million yuan.
The decline.
Among them, Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 70%.
There are 9 manufacturers of vinorelbine tartrate injection, including Jiangsu Haosen Pharmaceutical, Qilu Pharmaceutical (Hainan), and Beijing Shuanglu Pharmaceutical.
Hospital hospital hospitalcom, in recent years , the sales of Changchun Ruibin injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have exceeded 100 million yuan.
The growth rate in the first half of 2020 will be more than 100 million yuan.
The decline.
Among them, Jiangsu Hausen Pharmaceutical has the largest market share, exceeding 70%.
There are 9 manufacturers of vinorelbine tartrate injection, including Jiangsu Haosen Pharmaceutical, Qilu Pharmaceutical (Hainan), and Beijing Shuanglu Pharmaceutical.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of consistency evaluation, the supplementary application for consistency evaluation of vinorelbine tartrate injection of Qilu Pharmaceutical (Hainan) is currently under review and approval.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
